Russell Investments Group Ltd. Sells 9,114 Shares of Stevanato Group S.p.A. (NYSE:STVN)

Russell Investments Group Ltd. cut its holdings in Stevanato Group S.p.A. (NYSE:STVN) by 20.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 35,209 shares of the company’s stock after selling 9,114 shares during the quarter. Russell Investments Group Ltd.’s holdings in Stevanato Group were worth $912,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of the business. Truist Financial Corp grew its stake in shares of Stevanato Group by 27.0% in the first quarter. Truist Financial Corp now owns 16,645 shares of the company’s stock worth $431,000 after purchasing an additional 3,538 shares during the last quarter. Jump Financial LLC bought a new stake in shares of Stevanato Group in the first quarter worth about $663,000. Janney Montgomery Scott LLC grew its stake in shares of Stevanato Group by 14.2% in the first quarter. Janney Montgomery Scott LLC now owns 16,100 shares of the company’s stock worth $417,000 after purchasing an additional 2,000 shares during the last quarter. Simplex Trading LLC bought a new stake in shares of Stevanato Group in the first quarter worth about $44,000. Finally, Conestoga Capital Advisors LLC lifted its holdings in Stevanato Group by 1.9% in the first quarter. Conestoga Capital Advisors LLC now owns 3,537,141 shares of the company’s stock worth $91,612,000 after buying an additional 66,010 shares during the period. 10.90% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

STVN has been the subject of several research analyst reports. UBS Group raised their price objective on shares of Stevanato Group from $28.00 to $29.00 in a report on Friday, May 5th. Bank of America raised their price objective on shares of Stevanato Group from $32.00 to $35.00 in a report on Friday, June 16th. KeyCorp raised their price objective on shares of Stevanato Group from $35.00 to $37.00 and gave the stock an “overweight” rating in a report on Wednesday. Wells Fargo & Company raised their price objective on shares of Stevanato Group from $30.00 to $35.00 and gave the stock an “overweight” rating in a report on Monday, July 31st. Finally, Morgan Stanley lowered shares of Stevanato Group from an “overweight” rating to an “equal weight” rating and set a $34.00 target price for the company. in a report on Thursday, August 24th.

Stevanato Group Price Performance

STVN stock opened at €32.04 ($34.83) on Friday. The firm has a 50 day moving average price of €32.14 and a 200-day moving average price of €28.06. Stevanato Group S.p.A. has a 52-week low of €13.71 ($14.90) and a 52-week high of €36.30 ($39.46). The firm has a market capitalization of $9.47 billion, a price-to-earnings ratio of 55.24, a PEG ratio of 2.34 and a beta of 0.82. The company has a debt-to-equity ratio of 0.11, a quick ratio of 0.88 and a current ratio of 1.36.

Stevanato Group (NYSE:STVN) last announced its quarterly earnings data on Friday, July 28th. The company reported €0.15 ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of €0.14 ($0.15) by €0.01 ($0.01). Stevanato Group had a net margin of 14.24% and a return on equity of 15.12%. The company had revenue of €277.92 million during the quarter, compared to analyst estimates of €275.39 million. Equities research analysts forecast that Stevanato Group S.p.A. will post 0.64 EPS for the current fiscal year.

Stevanato Group Dividend Announcement

The company also recently disclosed an annual dividend, which was paid on Monday, July 17th. Investors of record on Tuesday, June 6th were issued a $0.0577 dividend. The ex-dividend date was Wednesday, June 7th. This represents a yield of 0.2%.

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for biopharma and healthcare. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines.